Zenas BioPharma, Inc. (ZBIO)
NASDAQ: ZBIO · Real-Time Price · USD
39.38
+1.27 (3.33%)
At close: Dec 5, 2025, 4:00 PM EST
39.98
+0.60 (1.52%)
After-hours: Dec 5, 2025, 6:51 PM EST
Zenas BioPharma Cash Flow Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| TTM
| FY 2024 | FY 2023 | FY 2022 |
| Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 |
| Net Income | -189.9 | -156.99 | -37.12 | -119.28 |
| Depreciation & Amortization | 0.08 | 0.14 | 0.11 | 0.08 |
| Asset Writedown & Restructuring Costs | 5 | - | 10 | 1 |
| Loss (Gain) From Sale of Investments | -2.11 | -0.6 | - | - |
| Stock-Based Compensation | 24.26 | 10.82 | 3.5 | 0.74 |
| Other Operating Activities | 2.59 | 1.53 | 1.03 | 43.85 |
| Change in Accounts Payable | -5.74 | 11.74 | -0.42 | 1.09 |
| Change in Other Net Operating Assets | 7.24 | 13.69 | -7.62 | 6.88 |
| Operating Cash Flow | -158.47 | -119.67 | -30.53 | -65.65 |
| Capital Expenditures | -0.09 | -0.13 | -0.02 | -0.2 |
| Sale (Purchase) of Intangibles | -5 | - | - | -2 |
| Investment in Securities | -157.17 | -30.42 | - | - |
| Investing Cash Flow | -162.26 | -30.55 | -0.02 | -2.2 |
| Long-Term Debt Issued | - | - | 20 | - |
| Net Debt Issued (Repaid) | 75 | - | 20 | - |
| Issuance of Common Stock | 9.09 | 240.91 | 0.12 | - |
| Other Financing Activities | -7.8 | -6.33 | - | - |
| Financing Cash Flow | 76.29 | 412.96 | 20.12 | 59.39 |
| Foreign Exchange Rate Adjustments | -0.12 | 0.16 | 0.08 | -0.04 |
| Net Cash Flow | -244.56 | 262.89 | -10.35 | -8.5 |
| Free Cash Flow | -158.57 | -119.81 | -30.55 | -65.85 |
| Free Cash Flow Margin | -1057.10% | -2396.10% | -61.09% | - |
| Free Cash Flow Per Share | -3.78 | -9.08 | -19.95 | -44.13 |
| Levered Free Cash Flow | -93.65 | -60.01 | -17.64 | - |
| Unlevered Free Cash Flow | -93.65 | -60.01 | -17.64 | - |
| Change in Working Capital | 1.5 | 25.43 | -8.04 | 7.97 |
Source: S&P Capital IQ. Standard template.
Financial Sources.